IntoCell, Inc.
- Biotech or pharma, therapeutic R&D
IntoCell is developing and commercialising of novel conjugate platform technologies (ADC) comprising proprietary linkers and payloads (Topo 1 and Duocarmycin), as well as novel ADCs (preclinical B7-H3 ADC) in their own right, and is seeking partner
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}